Catalyst Pharmaceutical Partners Company Profile (NASDAQ:CPRX)

Analyst Ratings

Consensus Ratings for Catalyst Pharmaceutical Partners (NASDAQ:CPRX) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $3.42 (360.03% upside)

Analysts' Ratings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/26/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$6.00 -> $1.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/22/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/20/2016SunTrust Banks Inc.Reiterated RatingBuy$7.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015MLV & Co.Initiated CoverageBuy$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2014AegisBoost Price TargetPositive$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q116($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.08)($0.06)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.09)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015Q414($0.07)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2014Q314($0.05)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/16/2014Q114($0.06)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/19/2014Q413($0.07)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.07)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/15/2013Q213($0.07)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/15/2012Q312($0.08)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.06)($0.06)($0.06)
Q2 20161($0.06)($0.06)($0.06)
Q3 20162($0.06)($0.06)($0.06)
Q4 20162($0.07)($0.06)($0.07)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/12/2016Charles B O'keeffeDirectorBuy20,000$0.81$16,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2016Philip H CoelhoDirectorBuy15,000$0.76$11,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Donald A DenkhausDirectorBuy50,000$0.65$32,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Patrick J McenanyCEOBuy105,300$0.65$68,445.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Charles B O'keeffeDirectorBuy20,000$0.60$12,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Patrick J McenanyCEOBuy50,000$0.65$32,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Philip H CoelhoDirectorBuy10,000$1.06$10,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Charles B O'keeffeDirectorBuy10,000$1.11$11,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Steve MillerCOOBuy7,933$1.80$14,279.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2016Charles B O'keeffeDirectorBuy5,000$1.94$9,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016Donald A DenkhausDirectorBuy25,000$2.03$50,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Patrick J McenanyCEOBuy25,000$2.39$59,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Charles B O'keeffeDirectorBuy5,000$2.41$12,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2015Charles B O'keeffeDirectorBuy5,000$2.30$11,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015M Douglas WinshipVPSell22,800$3.34$76,152.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Patrick J McenanyCEOBuy10,000$2.81$28,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015David D MuthEVPBuy1,700$3.20$5,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/30/2015Charles B O'keeffeDirectorBuy10,000$3.29$32,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/28/2015David D MuthEVPBuy2,000$3.55$7,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Donald A DenkhausDirectorBuy15,000$3.71$55,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Patrick J McenanyCEOBuy5,000$3.79$18,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Charles B O'keeffeDirectorBuy5,000$3.80$19,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/27/2015Donald A DenkhausDirectorBuy5,000$4.17$20,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015David D MuthEVPBuy21,000$2.96$62,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2015Charles B O'keeffeDirectorBuy10,000$3.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/8/2015Patrick J McenanyCEOBuy50,000$2.80$140,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/3/2014David D MuthVPBuy10,000$2.65$26,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2014Steve MillerCOOBuy100,000$2.17$217,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Patrick McenanyCEOBuy25,000$1.89$47,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Charles O'keeffeDirectorBuy10,000$1.83$18,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/16/2014Charles O'keeffeDirectorBuy5,000$2.02$10,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014Patrick McenanyCEOBuy25,000$1.82$45,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Charles O'keeffeDirectorBuy10,000$1.81$18,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013David S TierneyDirectorBuy8,000$2.03$16,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Charles B O'keeffeDirectorBuy10,000$1.84$18,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/21/2013Patrick J McenanyCEOBuy50,000$1.59$79,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2013Patrick J McenanyCEOBuy50,000$0.46$23,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2012Patrick J McenanyCEOBuy100,000$0.45$45,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2012Biomarin Pharmaceutical IncMajor ShareholderBuy5,000,000$0.75$3,750,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Patrick J McenanyCEOBuy100,000$0.42$42,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2012Philip H CoelhoDirectorBuy24,000$0.41$9,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Catalyst Pharmaceutical Partners (NASDAQ:CPRX)
DateHeadline
07/15/16 07:27 PMNew Broker Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - FTSE News
07/15/16 09:03 AMCrowd Rating and Earnings Recap for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Telanagana Press
07/14/16 07:40 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 11:35 AMNoteworthy Insider Transactions at 5 Companies Amid Slowing Insider Buying as Markets Near All-Time Highs -
07/12/16 08:48 PM2016 Q1 Sentiment Catalyst Pharmaceutical Partners Inc (NASDAQ:CPRX) - Consumer Eagle
07/12/16 07:41 AMTrading Performance and Target Watch for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph
07/12/16 07:41 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/12/16 07:41 AMNext Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard
07/07/16 08:37 PMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/07/16 08:37 PMBroker Outlook For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard
07/06/16 08:06 AMStock Rating Watch and Earnings Insight for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph
07/06/16 08:06 AMBroker Outlook For The Week Ahead Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard
06/30/16 10:34 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Company Rating and Target Watch - Telanagana Press
06/30/16 10:34 AMRecently Issued Stock Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Fiscal Standard
06/29/16 10:40 AMShare Update and Earnings Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Press Telegraph
06/28/16 08:16 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 04:02 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an -
06/23/16 02:44 PMCan Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Surprise Analysts this Quarter? - Investor Newswire
06/22/16 03:32 PMCatalyst Pharmaceutical Partners, Inc. (CPRX) Current Analyst Ratings - Fiscal Standard
06/10/16 04:02 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule -
06/10/16 04:02 PMCatalyst Pharmaceuticals, Inc. :CPRX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/07/16 03:49 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters t -
06/05/16 08:41 PMAfter Last Week What Do Analysts Think Of Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News
06/04/16 08:43 PMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) Stock Update & Estimates - Stock Tick Tock
06/02/16 09:22 PMStrong Sell Calls Count For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 0 - Investor Newswire - Strong Sell Calls Count For Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) At 0Investor NewswireCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) has a total of 3 Strong Buy calls and 0 Strong Sell advises as of 2016-06-01. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2 ...and more »
06/01/16 11:34 AMStock Review and Earnings Check on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - HNN - Stock Review and Earnings Check on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Catalyst Pharmaceutical Partners, ...and more »
05/30/16 12:34 PMCatalyst Pharmaceutical Partners, Inc. (CPRX) Broker Price Targets For The Coming Week - Share Trading News - Catalyst Pharmaceutical Partners, Inc. (CPRX) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Catalyst Pharmaceutical Partners, Inc. (CPRX). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 ...and more »
05/25/16 11:21 AMEarnings Review and Stock Rundown for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Earnings Review and Stock Rundown for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Catalyst Pharmaceutical Partners, Inc.and more »
05/23/16 01:27 PMStock Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Stock Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1.5 on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research.and more »
05/18/16 12:00 PMShare Recap and Earnings Focus on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Share Recap and Earnings Focus on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsPresently, covering analysts are anticipating Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) to report quarterly EPS of $-0.07. The company's next earnings report is expected to be released on or around 2016-08-08 for the period ending on ...and more »
05/18/16 08:52 AMCatalyst Pharmaceutical's Firdapse Phase 3 Study Published in Muscle & Nerve - [at noodls] - May 18, 2016 CORAL GABLES, Fla., May 18, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
05/18/16 08:22 AMCatalyst (CPRX) Resorts to Layoffs for Firdapse Development -
05/18/16 07:03 AMCatalyst Pharmaceutical’s Firdapse Phase 3 Study Published in Muscle & Nerve - [GlobeNewswire] - CORAL GABLES, Fla., May 18, 2016-- Catalyst Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, ...
05/17/16 04:20 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial -
05/17/16 07:42 AMCatalyst Pharmaceuticals Announces Reduction in Workforce as Part of Operating Expense Management Plan - [at noodls] - May 17, 2016 CORAL GABLES, Fla., May 17, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
05/16/16 01:49 PMConsensus Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - Wall Street Hints and News - Consensus Rating Review for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1.5 on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate ...and more »
05/15/16 05:38 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) One-Year Mean Price Target At $5.25 - Stocks Daily - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) One-Year Mean Price Target At $5.25Stocks DailySell-side analysts are confident on the future outlook of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) stock. As of 2016-05-13, the stock has an ABR of 1.5 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the ...and more »
05/11/16 02:29 PMCatalyst (CPRX) Posts In-Line Q1 Loss, Firdapse in Focus -
05/10/16 05:35 PMCatalyst reports 1Q loss -
05/10/16 04:47 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
05/10/16 04:08 PMCatalyst Pharmaceuticals Announces First Quarter 2016 Financial Results and Provides Corporate Update - [at noodls] - May 10, 2016 CORAL GABLES, Fla., May 10, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative ...
05/10/16 03:51 PMCATALYST PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/10/16 06:07 AMQ1 2016 Catalyst Pharmaceuticals Inc Earnings Release - After Market Close -
05/10/16 05:36 AMCheck on Analyst Ratings Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Check on Analyst Ratings Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1.5 on shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on ...and more »
05/10/16 05:36 AMPerformance Recap and Target Perspective on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialIn the latest trading session, shares of Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) moved +4.519%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a ...and more »
05/08/16 05:20 AMCatalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ABR Of 1.5 - Stocks Daily - Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) ABR Of 1.5Stocks DailyThere are numerous brokerages operating in the market, and each one of them uses a different process to prepare the research reports on a stock. As a result, investors have to study more than one research report before taking an investment call on a stock.and more »
05/06/16 07:14 AMCatalyst Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Wednesday, May 11th, 2016 - [at noodls] - May 6, 2016 CORAL GABLES, Fla., May 06, 2016 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies ...
05/03/16 05:23 AMAverage Analyst Rating for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) - B.O.D.Y Confidential - Average Analyst Rating for Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1.5 on Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/03/16 05:23 AMThis Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News - The Point ReviewThis Weeks Broker Price Targets For Catalyst Pharmaceutical Partners, Inc. (CPRX)Share Trading News04/26/2016 – Catalyst Pharmaceutical Partners, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 1 price target on the stock. 02/18/2016 – Catalyst Pharmaceutical Partners, Inc. had its “buy” rating reiterated by ...Catalyst Pharmaceuticals Inc's Stock Formed A Several Months Bearish Wedge Down Chart PatternFranklin Independentall 3 news articles »
04/28/16 05:37 AMLatest Analyst Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX) - Share Trading News - Latest Analyst Ratings For Catalyst Pharmaceutical Partners, Inc. (CPRX)Share Trading News04/26/2016 – Catalyst Pharmaceutical Partners, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 1 price target on the stock. 02/18/2016 – Catalyst Pharmaceutical Partners, Inc. had its “buy” rating reiterated by ...

Social

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners logoCatalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $0.74
  • 50 Day Moving Average: $0.7591
  • 200 Day Moving Average: $1.0812
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $60.71M
  • Beta: 1.23
  • Current Year EPS Consensus Estimate: $-0.29 EPS
  • Next Year EPS Consensus Estimate: $-0.31 EPS
Additional Links:
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Chart for Thursday, July, 28, 2016